Johnson & Johnson has put $30B on the table for Actelion (OTCPK:ALIOY) in a deal that will also spin off the Swiss firm's R&D unit. The all-cash offer, valued at $280 per Actelion share, will be payable in U.S. dollars and was unanimously approved by the boards of both companies. J&J (NYSE:JNJ) further outlined that the transaction will be financed by cash held outside of the United States. Actelion shares +20% in Zurich.
Submitted January 27, 2017 at 09:00AM by st3v1s http://ift.tt/2kB4z6x
